Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

Autor: I. Blancas, C. Olier, V. Conde, J. L. Bayo, C. Herrero, I. Zarcos-Pedrinaci, F. Carabantes, J. M. Baena-Cañada, J. Cruz, M. Ruiz-Borrego

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)

Abstract Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patie

Externí odkaz: https://doaj.org/article/ed9027d233a645fe8b379093aa99b6f0

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

Autor: Noelia Martínez-Jañez, E. Martínez de Dueñas, F. Carabantes, L. Murillo, José A. García-Sáenz, R. Fonseca, Joaquín Gavilá, Eva Ciruelos, Maria Vidal, Yolanda Fernández, A. Beliera

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer. It is necessary, therefore, to characterize the safety profile of this new co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79938308c818a703dcebff2328f73ae3
https://pubmed.ncbi.nlm.nih.gov/29116433

MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer

Autor: A. Caballero, A. Alonso, F. Carabantes, R. Lavado-Valenzuela, M. Benavides

Publikováno v: Tissue antigens. 74(1)

The NKG2D-major histocompatibility complex class I-related chain A (MICA) system plays a key role in the antitumoral immune response. We studied five alleles of a microsatellite in the MICA transmembrane region; one of which (MICA-A5.1) gives rise to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc9a3528deb39198dea9ba603deb1db
https://pubmed.ncbi.nlm.nih.gov/19392799

Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study

Autor: F Carabantes-Ocón, A Casaus-Hazañas, S Luna, L Burgos-Garcia, E Villar-Chamorro, E Saez-Lara, C Martínez

Objective: To study the benefit of trastuzumab in monotherapy or combined with different chemotherapeutic agents in the treatment for Her2+ metastatic breast cancer (MBC) patients after progression on prior trastuzumab therapy. Yes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b0ad1689c177b21eae87db82e57d55
https://hdl.handle.net/10668/804

Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer

Autor: P. García-Alfonso, G. Pérez-Manga, F. Carabantes, A. Muñoz-Martín, M. Balcells, E. Villar, M. Cobo, S. Gil-Calle, J. Graupera, M. Benavides

Publikováno v: Medical oncology (Northwood, London, England). 21(3)

Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC). Little is known about its efficacy and safety in previously treated patients with poor performance status. We prospectively evaluated the antitumor efficacy a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778522c5d130068521455903024c23a7
https://pubmed.ncbi.nlm.nih.gov/15456953